이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

무릎 골관절염에서 단일 vs 삼중 히알루론산 (DR-HAKOA)

2026년 11월 3일 업데이트: University of Erlangen-Nürnberg Medical School

무릎 골관절염 치료에서 단일 대 삼중 히알루론산 주사의 효과와 안전성

The goal of this clinical trial is to directly compare two hyaluronic acid injection protocols in adults with knee osteoarthritis: a single intra-articular injection of Innoryos 2.5% (Single-Shot) and a three-week injection series of Innoryos 2.2% (Triple-Shot). The study aims to determine whether the single injection provides comparable safety, pain relief, and improvement in knee function to the triple-injection protocol.

The main questions are:

  • How do the single-shot and triple-shot protocols compare in terms of pain reduction and functional improvement?
  • How do their safety and tolerability profiles compare?
  • What medical problems occur with each protocol? Participants (n = 46) will receive either the single 4.8 ml injection or three weekly 2 ml injections. They will attend clinic visits at baseline, Week 6, Week 12, and Week 24 for assessments including WOMAC score, 7-day pain diary, functional and strength tests, and MRI scans of the knee.

This single-center, partially blinded, randomized study will provide a direct comparison of the two HA injection protocols, assessing whether the single-shot approach is as safe and effective as the triple-shot regimen, while potentially offering a more convenient, patient-friendly treatment.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

Background:

Knee osteoarthritis (gonarthrosis) is a prevalent degenerative joint disease characterized by cartilage loss, joint pain, stiffness, and functional impairment, which significantly affects mobility and quality of life. Intra-articular injections of hyaluronic acid (HA) are a well-established conservative therapy to reduce pain, improve function, and potentially delay surgical interventions. Various HA formulations and injection protocols exist, differing in molecular weight, concentration, and dosing schedules. Optimizing treatment in terms of efficacy, safety, patient convenience, and cost-effectiveness remains a key clinical goal.

Objective:

This study aims to compare the safety, tolerability, and efficacy of a single intra-articular injection of Innoryos 2.5% (Single-Shot) with a standard three-week injection regimen of Innoryos 2.2% (Triple-Shot) in adults with moderate to severe knee osteoarthritis. The primary focus is on safety and pain reduction, with secondary outcomes including functional improvement, leg muscle strength, and structural assessment of the knee joint via MRI.

Study Design:

This is a single-center, randomized, partially blinded, parallel-group clinical intervention study including 46 participants. Patients are randomized using block randomization stratified by baseline WOMAC total score to ensure balanced distribution of baseline pain and functional impairment. Patients and treating physicians are aware of treatment allocation, while all personnel performing functional tests, MRI assessments, data entry, and statistical analyses are blinded to minimize bias.

Participants:

Adults aged 40-70 years with radiographically confirmed moderate to severe knee osteoarthritis, experiencing knee pain for at least three months and on at least 50% of days in the prior month. Key exclusion criteria include grade 4 osteoarthritis, non-osteoarthritic knee pain, other rheumatic diseases, recent HA or corticosteroid injections, recent trauma or surgery, coagulopathies, autoimmune disorders, pregnancy or lactation, and contraindications for MRI.

Interventions:

  • Single-Shot Group: One intra-articular injection of Innoryos 2.5% (4.8 ml)
  • Triple-Shot Group: Three intra-articular injections of Innoryos 2.2% (2 ml each) at weekly intervals

Outcomes:

The primary outcome is total WOMAC score. Secondary outcomes include WOMAC subscales, VAS pain diary, functional performance, leg muscle strength, MRI-detected structural changes, and safety/tolerability parameters.

Assessments:

Participants are assessed at baseline, Week 6, Week 12, and Week 24.

  • WOMAC questionnaire (baseline, Week 6, Week 12, and Week 24): Pain, stiffness, and functional limitation
  • Pain diary (VAS) (baseline, Week 6, Week 12, and Week 24): Daily for 7 days at each assessment (~1 min/day)
  • Functional and strength tests (baseline, Week 6, Week 12): Chair Stand Test, Timed Up and Go Test, isokinetic leg press (~30 min per session)
  • MRI (baseline, Week 6, Week 12): Baseline and Week 12 for structural assessment (~90 min including functional tests)
  • Safety monitoring: Adverse events, medication use, compliance, drop-outs

Significance:

This study provides high-quality evidence for the direct comparison of single-shot versus triple-shot HA injection protocols in knee osteoarthritis. By using stratified randomization based on baseline WOMAC total score and blinded assessment of outcomes, the trial ensures unbiased evaluation. Demonstration of comparable safety and efficacy of the single-shot regimen could offer a more convenient, patient-friendly, and potentially safer therapeutic option, optimizing conservative management for patients with knee osteoarthritis.

intra-articular injection of Innoryos 2.5% (Single-Shot) with a standard three-week injection regimen of Innoryos 2.2% (Triple-Shot) in adults with moderate to severe knee osteoarthritis. The primary focus is on safety and pain reduction, with secondary outcomes including functional improvement, leg muscle strength, and structural assessment of the knee joint via MRI.

Study Design:

This is a single-center, randomized, partially blinded, parallel-group clinical intervention study including 46 participants. Patients are randomized using block randomization stratified by baseline WOMAC total score to ensure balanced distribution of baseline pain and functional impairment. Patients and treating physicians are aware of treatment allocation, while all personnel performing functional tests, MRI assessments, data entry, and statistical analyses are blinded to minimize bias.

Participants:

Adults aged 40-70 years with radiographically confirmed moderate to severe knee osteoarthritis, experiencing knee pain for at least three months and on at least 50% of days in the prior month. Key exclusion criteria include grade 4 osteoarthritis, non-osteoarthritic knee pain, other rheumatic diseases, recent HA or corticosteroid injections, recent trauma or surgery, coagulopathies, autoimmune disorders, pregnancy or lactation, and contraindications for MRI.

연구 유형

중재적

등록 (실제)

46

단계

  • 2 단계
  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Erlangen, 독일, 91052
        • Institute of Radiology, University Hospital Erlangen

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

40년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults aged 40-70 years
  • Radiographically confirmed moderate to severe knee osteoarthritis
  • Knee pain for ≥3 months
  • Pain on ≥50% of days in past 30 days
  • Able to provide informed consent

Exclusion Criteria:

  • Grade 4 osteoarthritis (full-thickness cartilage loss)
  • Non-osteoarthritic knee pain
  • Other rheumatic diseases (e.g., rheumatoid arthritis, fibromyalgia)
  • HA injection <6 months or corticosteroid injection <3 months in target knee
  • Recent trauma or surgery of affected knee (<6 months)
  • Coagulopathy or bleeding disorder
  • Autoimmune or relevant systemic disease
  • Dermatologic infection at injection site
  • Pregnancy or lactation
  • Opioid or oral corticosteroid use
  • Contraindications to MRI (pacemaker, intracorporeal metal, claustrophobia)
  • Expected absence during study period or noncompliance

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Three intra-articular HA injections

Three intra-articular injections of Innoryos 2.2% (2 ml each) in the knee joint at weekly intervals

Therapy with intra-articular injections of hyaluronic acid (HA). Three intra-articular injections of Innoryos 2.2% (2 ml per injection) administered into the affected knee joint at weekly intervals.

실험적: One intra-articular HA injection

One intra-articular injection of Innoryos 2.5% (4.8 ml) in the knee joint

Therapy with a single intra-articular injection of hyaluronic acid (HA). One intra-articular injection of Innoryos 2.5% (4.8 ml per injection) administered into the affected knee joint at weekly intervals.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
WOMAC questionnaire total score
기간: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Total score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing overall pain, stiffness, and physical function of the knee joint

At baseline, at 6 weeks, at 12 weeks, at 24 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
WOMAC questionnaire pain subscore
기간: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Pain subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing pain of the knee joint

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
WOMAC questionnaire stiffness subscore
기간: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Stiffness subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing stiffness of the knee joint

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
WOMAC questionnaire physical function subscore
기간: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Physical function subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing pain of the knee joint

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
7-day pain assessment using visual analog scale (VAS)
기간: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Participants will record their knee pain daily using a Visual Analog Scale (VAS) as part of a 7-day pain diary at each assessment period. The VAS is a straight 100 mm line, anchored by "no pain" at 0 mm and "worst imaginable pain" at 100 mm. Participants indicate their current knee pain intensity each day by marking a point on the line that best represents their pain.

The diary is completed for seven consecutive days to capture fluctuations in pain intensity during daily activities. The daily VAS scores are recorded and later averaged to calculate a weekly mean pain score.

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
Maximum isokinetic leg extension strength
기간: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Participants' leg muscle strength and functional performance are assessed using an isokinetic leg press (Physiomed, Laipersdorf, Germany). Before testing, participants complete a 5-minute warm-up on a cross-trainer to prepare the muscles and reduce injury risk.

Following the warm-up, two maximal test sessions are conducted, each consisting of 6 repetitions at a velocity of 0.6 meters per second (m/s). During each attempt, participants perform the leg press extension movement with maximal effort. The highest peak force achieved during the extension in each session is recorded and used for analysis.

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
30-Second Chair Stand Test (30s CST) - Assessment of Lower Limb Function:
기간: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

The 30-Second Chair Stand Test measures lower body strength, endurance, and functional mobility. Participants sit on a standard chair with arms crossed over the chest. When instructed, they stand up fully and sit back down repeatedly for 30 seconds.

The total number of full stands completed within 30 seconds is recorded. A higher number of repetitions indicates better lower limb strength and functional performance.

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
Knee MRI and T2 Mapping - Assessment of Joint Structures
기간: At baseline, at 12 weeks, at 24 weeks

Magnetic Resonance Imaging (MRI) is used to assess structural changes in the knee joint and evaluate the integrity of cartilage and other joint tissues. Participants undergo a non-invasive, radiation-free MRI scan of the affected knee at baseline and 12 weeks after treatment.

The MRI protocol includes high-resolution imaging of joint structures, such as cartilage, menisci, ligaments, and subchondral bone. Additionally, T2 mapping is performed to quantify the T2 relaxation time of articular cartilage, which reflects the water content and collagen organization. Areas of increased T2 values indicate cartilage degeneration or changes in cartilage composition, while decreases or stabilization suggest maintenance or improvement of cartilage health.

At baseline, at 12 weeks, at 24 weeks

기타 결과 측정

결과 측정
측정값 설명
기간
Compliance and Drop-Out
기간: up to 24 weeks

Compliance refers to the degree to which participants adhere to the assigned injection protocol and scheduled study visits. For the Single-Shot group, compliance is assessed by confirming that participants receive the planned single 4.8 ml injection at baseline. For the Triple-Shot group, compliance is assessed by verifying that participants receive all three weekly 2 ml injections according to the study schedule. Compliance is documented in the study records and serves as a measure of treatment adherence and feasibility of the respective protocols.

Drop-Out refers to participants who withdraw from the study before completion or fail to attend follow-up assessments at the scheduled time points (baseline, Week 6, Week 12, Week 24). Reasons for drop-out, including adverse events, personal choice, or loss to follow-up, are recorded. Drop-out rates are analyzed as an endpoint to evaluate the acceptability, tolerability, and practicality of each

up to 24 weeks
Medication Use - Analgesic Tracking
기간: Up to 24 weeks

Participants record their use of pain medications during the 7-day pain diary period, which accompanies the daily Numeric Rating Scale (NRS) for knee pain. Each day, participants document:

The type of pain medication taken The dosage The timing of administration

Up to 24 weeks
Adverse Effects - Safety Endpoint
기간: Up to 24 weeks

Adverse effects are monitored to assess the safety and tolerability of the hyaluronic acid injection protocols. Participants are instructed to report any adverse events or reactions following the injections. Specifically:

Short-term monitoring: Participants record any adverse effects daily for 7 days after each injection. This includes local reactions at the injection site (e.g., pain, swelling, redness) as well as any systemic symptoms (e.g., fatigue, fever).

Long-term monitoring: Adverse effects are also tracked throughout the entire study duration.

All reported adverse events are documented, classified, and analyzed according to severity, duration, and possible relation to the treatment.

Up to 24 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Simon von Stengel, PhD, Institute of Radiology, University Hospital Erlangen, Germany

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 15일

기본 완료 (추정된)

2026년 12월 15일

연구 완료 (추정된)

2026년 12월 31일

연구 등록 날짜

최초 제출

2026년 1월 2일

QC 기준을 충족하는 최초 제출

2026년 1월 13일

처음 게시됨 (실제)

2026년 1월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 1월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 25-275_1-Bm

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data (IPD) from this study will not be shared publicly in order to comply with data protection regulations in Germany (GDPR) and the study's data protection consent. Only aggregated and anonymized results will be reported in publications or study summaries. No personal identifiers, contact information, or sensitive participant data will be disclosed.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .